An Open-Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 19 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Oct 2018.
- 19 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Oct 2018.
- 24 Aug 2017 New trial record